-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 26, the NMPA official website released the latest drug approval information, and Chengdu Better Pharmaceutical's cefepime hydrochloride for injection passed the consistency evaluation
.
This product is a fourth-generation cephalosporin anti-infective drug.
Up to now, there are 4 companies that have been evaluated.
Whether it will become the target of the seventh batch of national procurement has attracted market attention.
The first five batches and six rounds (excluding insulin specific) Cai has included 12 cephalosporin products, of which 4 are injections
.
Figure 1: Current situation of companies that have been reviewed for cefepime hydrochloride for injection.
Source: Menet.
com consistency evaluation database.
Cefepime hydrochloride for injection belongs to the fourth-generation cephalosporin anti-infective drug, which is initiated by inhibiting the synthesis of bacterial cell walls.
In terms of bactericidal effect, it has the characteristics of broad antibacterial spectrum, strong activity against Gram-positive and negative bacteria, and stability to β-lactamase.
It is clinically mainly used for the treatment of sensitive bacteria caused by adults and children aged 2 months to 16 years.
Moderate to severe infection
.
According to data from Menet.
com, in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions), the sales peak of cefepime hydrochloride for injection reached 910 million yuan in 2015.
The policy of "limited delivery and limited resistance" has affected the sales of cephalosporin injections, but there are still sales of more than 100 million yuan
.
Table 1: The situation of cephalosporin injections that have been included in national procurement.
Source: Meinenet.
com.
The first five batches and six rounds of national procurement in the terminal competition pattern of national procurement.
Each round has cephalosporin products.
The fifth batch includes injections for the first time, 4 The winning products are all TOP10 terminal cephalosporin injection products in China's public medical institutions in the first half of 2021
.
As more and more cephalosporin injections are reviewed, the new round of national procurement will focus on this again
.
Earlier, the domestic cephalosporin drug market has always been subject to many approvals and fierce competition.
The winning bid for centralized procurement is expected to maintain its market position, while the market share of enterprises that lose the bid or even have not passed the evaluation will be further robbed.
.
According to data from Meinenet, there are currently more than 30 domestic companies that have obtained approval for cefepime hydrochloride for injection.
The companies with a market share of more than 10% in the first half of 2021 are Shenzhen Xinlitai Pharmaceutical, Shanghai Xinfeng Pharmaceutical, and Baiyunshan Tianxin Pharmaceutical.
, Shenzhen Lijian Pharmaceutical and Shandong Luoxin Pharmaceutical Group.
In addition to Xinlitai, Qilu Pharmaceutical, Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical are among the companies that have been reviewed.
If the product is included in the new round of national procurement, The market shuffling is on the verge
.
Table 2: The situation of cephalosporin products reviewed by Chengdu Better Pharmaceutical Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, the number of cephalosporin products reviewed by Chengdu Better Pharmaceutical has reached 12, the third The batch and the fifth batch of Guocai won the bids for 1 and 3 products respectively, and the company has 7 cephalosporin products that have been reviewed to meet the challenge of the new Guocai
.
Source: NMPA official website, Minet.
com database.
The review data statistics are as of November 24.
If there are any errors or omissions, please correct me
.
.
This product is a fourth-generation cephalosporin anti-infective drug.
Up to now, there are 4 companies that have been evaluated.
Whether it will become the target of the seventh batch of national procurement has attracted market attention.
The first five batches and six rounds (excluding insulin specific) Cai has included 12 cephalosporin products, of which 4 are injections
.
Figure 1: Current situation of companies that have been reviewed for cefepime hydrochloride for injection.
Source: Menet.
com consistency evaluation database.
Cefepime hydrochloride for injection belongs to the fourth-generation cephalosporin anti-infective drug, which is initiated by inhibiting the synthesis of bacterial cell walls.
In terms of bactericidal effect, it has the characteristics of broad antibacterial spectrum, strong activity against Gram-positive and negative bacteria, and stability to β-lactamase.
It is clinically mainly used for the treatment of sensitive bacteria caused by adults and children aged 2 months to 16 years.
Moderate to severe infection
.
According to data from Menet.
com, in China’s urban public hospitals, county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions), the sales peak of cefepime hydrochloride for injection reached 910 million yuan in 2015.
The policy of "limited delivery and limited resistance" has affected the sales of cephalosporin injections, but there are still sales of more than 100 million yuan
.
Table 1: The situation of cephalosporin injections that have been included in national procurement.
Source: Meinenet.
com.
The first five batches and six rounds of national procurement in the terminal competition pattern of national procurement.
Each round has cephalosporin products.
The fifth batch includes injections for the first time, 4 The winning products are all TOP10 terminal cephalosporin injection products in China's public medical institutions in the first half of 2021
.
As more and more cephalosporin injections are reviewed, the new round of national procurement will focus on this again
.
Earlier, the domestic cephalosporin drug market has always been subject to many approvals and fierce competition.
The winning bid for centralized procurement is expected to maintain its market position, while the market share of enterprises that lose the bid or even have not passed the evaluation will be further robbed.
.
According to data from Meinenet, there are currently more than 30 domestic companies that have obtained approval for cefepime hydrochloride for injection.
The companies with a market share of more than 10% in the first half of 2021 are Shenzhen Xinlitai Pharmaceutical, Shanghai Xinfeng Pharmaceutical, and Baiyunshan Tianxin Pharmaceutical.
, Shenzhen Lijian Pharmaceutical and Shandong Luoxin Pharmaceutical Group.
In addition to Xinlitai, Qilu Pharmaceutical, Hengrui Pharmaceutical, and Chengdu Better Pharmaceutical are among the companies that have been reviewed.
If the product is included in the new round of national procurement, The market shuffling is on the verge
.
Table 2: The situation of cephalosporin products reviewed by Chengdu Better Pharmaceutical Source: Meinenet MED2.
0 Chinese Drug Evaluation Database Up to now, the number of cephalosporin products reviewed by Chengdu Better Pharmaceutical has reached 12, the third The batch and the fifth batch of Guocai won the bids for 1 and 3 products respectively, and the company has 7 cephalosporin products that have been reviewed to meet the challenge of the new Guocai
.
Source: NMPA official website, Minet.
com database.
The review data statistics are as of November 24.
If there are any errors or omissions, please correct me
.
